NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT

Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT
Credit: Milestone Pharmaceuticals
Already have an account? Sign in.
12/15/2025 · 5:50 AM
MIST
/ Don’t stop at just one post.

Related↓

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
04/10/2026 · 7:14 AM

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)

Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.

/ Subscriber only
/ Read more

Feed↓

Spotify Q1 2026 Earnings Beat Expectations — But Q2 Outlook Misses Wall Street Estimates
04/28/2026 · 6:32 AM

Spotify Q1 2026 Earnings Beat Expectations — But Q2 Outlook Misses Wall Street Estimates

Spotify had strong Q1 2026 results but warned Q2 growth will slow and miss forecasts, sending shares down about 9%.

/ Subscriber only
Starboard Value Takes Aim at Dynatrace: Activist Push for Big Stock Boost
04/28/2026 · 6:09 AM

Starboard Value Takes Aim at Dynatrace: Activist Push for Big Stock Boost

Starboard Value pushes Dynatrace to cut costs and boost buybacks to lift its struggling stock despite strong AI potential.

/ Subscriber only
OpenAI Misses Sales and User Targets, Drags Partner Stocks Down
Featured/ 04/28/2026 · 5:42 AM

OpenAI Misses Sales and User Targets, Drags Partner Stocks Down

OpenAI missed growth targets, worrying investors as rivals rise and AI costs stay high, raising doubts about quick profits. Shares of SoftBank, Oracle, and AMD dropped sharply.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe